Q1 Earnings Forecast for CELZ Issued By Roth Capital

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Stock analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Creative Medical Technology in a report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff expects that the company will earn ($0.64) per share for the quarter. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.29) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.54) EPS and Q4 2025 earnings at ($0.54) EPS.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ opened at $2.70 on Friday. The business’s fifty day moving average price is $3.47 and its 200-day moving average price is $3.70. Creative Medical Technology has a one year low of $2.52 and a one year high of $10.28. The stock has a market capitalization of $4.73 million, a PE ratio of -0.71 and a beta of 2.01.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC boosted its holdings in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,570 shares of the company’s stock after buying an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned approximately 1.45% of Creative Medical Technology worth $75,000 as of its most recent filing with the Securities and Exchange Commission. 1.42% of the stock is owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.